Profusa Partners with Spanish Distributor for Lumee Oxygen
Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a leading digital health company based in Berkeley, California, has made a significant advancement by signing a Letter of Intent (LOI) to form a distribution partnership in Spain. This collaboration will support the distribution of their innovative Lumee Oxygen platform through Dismeval, S.L., a well-established distributor of medical and surgical equipment.
Significance of the Distribution Agreement
The partnership with Dismeval marks an exciting milestone for Profusa as it seeks to solidify its presence in the European market. Dismeval has proven expertise and a dedicated team with extensive knowledge within the medical device sector, particularly in clinical settings. This strategic alliance is designed to pave the way for Profusa's groundbreaking technology to reach hospitals and medical facilities across Spain, including the Canary and Balearic Islands.
Healthcare Impact and Business Growth
Ben Hwang, Ph.D., Profusa’s Chairman and CEO, expressed enthusiasm about the partnership, stating, "Establishing a distributor partner in Spain for our Lumee Oxygen platform is the first, tangible step as we build a robust distribution infrastructure in Europe." He elaborates on the enormous potential of this market, with an estimated global addressable market exceeding $10.5 billion for their tissue oxygen technology, which addresses crucial medical needs across multiple indications such as peripheral artery disease, chronic wounds, and critical limb ischemia.
European Market Insights
The healthcare landscape in Europe is ripe for innovation, with over 300,000 endovascular procedures performed annually. This high demand presents substantial opportunities for growth in Profusa's portfolio. The distribution agreement aligns neatly with the company's goal to deliver real-time personal healthcare technologies that can greatly benefit patients and healthcare providers alike.
About Profusa and Its Innovations
Profusa stands out within the digital health industry for its commitment to developing a new generation of tissue-integrated sensors. These sensors are engineered to detect and continuously relay clinical-grade data to inform personal and medical care. The company leverages cutting-edge technology and an intelligent data platform to cultivate personalized biochemical signatures. This innovation is facilitated by their injectable, long-lasting, and affordable biosensors, which enhance clinician reliability and patient trust.
Company’s Vision and Future Goals
Profusa envisions a future where continuous monitoring and instant feedback from biosensors will revolutionize patient care. As they expand into new territories like Spain, the focus on building reliable healthcare solutions remains steadfast. Their forward-thinking approach aims to create a healthier world through the intersection of technology and medicine.
Frequently Asked Questions
What is the Lumee Oxygen platform?
The Lumee Oxygen platform developed by Profusa facilitates real-time monitoring of tissue oxygenation, aiding in timely medical interventions.
Who is the distributor for Profusa in Spain?
Dismeval S.L. is the dedicated distributor for Profusa’s Lumee Oxygen platform in Spain, leveraging its medical expertise for successful implementation.
What markets does Profusa target with its technology?
Profusa targets critical healthcare markets facing challenges like peripheral artery disease, chronic wounds, and critical limb ischemia through its innovative technologies.
How does Profusa ensure the reliability of its biosensors?
Profusa's biosensors are designed for long-lasting use and provide actionable, medical-grade data that clinicians can trust for better patient outcomes.
What are Profusa's future expansion plans?
Profusa intends to build strong distribution networks across Europe to facilitate access to its biosensor technology and enhance patient care availability globally.
